Discover
DMRA
Damora Therapeutics, Inc.
27.09
2 x 19.93
2 x 33.39
bid
ask
+
1.08
4.15%
2 @ 04:00 PM
26.57 -0.52 (1.92%)
| Ytd | 17.73% | |
| 1y | 694.43% |
25.76
day range
28.43
2.45
52 week range
38.33
| Open | 26.10 | Prev Close | 26.01 | Low | 25.76 | High | 28.43 | Mkt Cap | 1.67B |
| Vol | 579.61K | Avg Vol | 501.75K | EPS | -2.68 | P/E | N/A | Forward P/E | -12.52 |
| Beta | 1.48 | Short Ratio | 3.49 | Inst. Own | 91.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 23.83 | 200-d Avg | 21.25 | 1yr Est | 43.38 |
DMRA News
globenewswire.com
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a bio
benzinga.com
Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $35 Price Target
Wedbush analyst David Nierengarten reiterates Damora Therapeutics (NASDAQ:DMRA) with a Outperform
benzinga.com
HC Wainwright & Co. Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Targe
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Damora Therapeutics (NAS